Company news

Share this article:
Schering-Plough Corporation announced that it has received antitrust clearance from the Federal Trade Commission regarding its planned acquisition of Organon BioSciences from Akzo Nobel as announced March 12. Organon BioSciences is comprised mainly of Organon, the human pharmaceutical business, and Intervet, the animal health business. It also includes Nobilon, the human vaccine development unit, and Diosynth, the third- party manufacturing unit of Organon. Schering-Plough received approval from The European Commission on Oct. 11, and continues to expect the transaction to be completed by year-end 2007.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.